Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May 18;11(1):66.
doi: 10.1186/s13023-016-0445-8.

The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network

Peter A Merkel  1 , Michele Manion  2 , Rashmi Gopal-Srivastava  3 , Stephen Groft  4 , H A Jinnah  5 , David Robertson  6 , Jeffrey P Krischer  7 ; Rare Diseases Clinical Research Network
Affiliations

The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network

Peter A Merkel et al. Orphanet J Rare Dis. .

Abstract

Background: Among the unique features of the Rare Diseases Clinical Research Network (RDCRN) Program is the requirement for each Consortium to include patient advocacy groups (PAGs) as research partners. This development has transformed the work of the RDCRN and is a model for collaborative research. This article outlines the roles patients and PAGs play in the RDCRN and reports on the PAGs' impact on the Network's success.

Methods: Principal Investigators from the 17 RDCRN Consortia and 28 representatives from 76 PAGs affiliated with these Consortia were contacted by email to provide feedback via an online RDCRN survey. Impact was measured in the key areas of 1) Research logistics; 2) Outreach and communication; and 3) Funding and in-kind support. Rating choices were: 1-very negative, 2-somewhat negative, 3-no impact, 4-somewhat positive, and 5-very positive.

Results: Twenty-seven of the PAGs (96 %) disseminate information about the RDCRN within the patient community. The Consortium Principal Investigators also reported high levels of PAG involvement. Sixteen (94 %) Consortium Principal Investigators and 25 PAGs (89 %) reported PAGs participation in protocol review, study design, Consortium conference calls, attending Consortium meetings, or helping with patient recruitment.

Conclusions: PAGs are actively involved in shaping Consortia's research agendas, help ensure the feasibility and success of research protocols by assisting with study design and patient recruitment, and support training programs. This extensive PAG-Investigator partnership in the RDCRN has had a strongly positive impact on the success of the Network.

Keywords: Network; Patient engagement; Rare diseases.

PubMed Disclaimer

References

    1. Health Promotion and Disease Prevention Amendments of 1984, Pub. L. No. 98–551, 98 Stat. 2815 (Oct. 30, 1984).
    1. Groft SC, Gopal-Srivastava R. A model for collaborative clinical research in rare diseases: experience from the Rare Disease Clinical Research Network program. J Clin Invest. 2013;3(11):1015–21. doi: 10.4155/cli.13.101. - DOI
    1. Krischer JP, Gopal-Srivastava R, Groft SC, Eckstein DJ, Rare Diseases Clinical Research Network The Rare Diseases Clinical Research Network's organization and approach to observational research and health outcomes research. J Gen Intern Med. 2014;29(Suppl 3):S739–44. doi: 10.1007/s11606-014-2894-x. - DOI - PMC - PubMed
    1. Akers A, Ball KL, Clancy M, et al. Brain Vascular Malformation Consortium: overview, progress, and future directions. J Rare Disord. 2013;1(1):1–15. - PMC - PubMed
    1. Chronic Graft Versus Host Disease Consortium Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. Biol Blood Marrow Transplant. 2011;17(8):1114–20. doi: 10.1016/j.bbmt.2011.05.007. - DOI - PMC - PubMed